Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 40 of the 56 sources its claims cite were checked for support.
Abstract
BACKGROUND: Heart failure with preserved ejection fraction is increasing in prevalence and is associated with a high symptom burden and functional impairment, especially in persons with obesity. No therapies have been approved to target obesity-related heart failure with preserved ejection fraction. METHODS: We randomly assigned 529 patients who had heart failure with preserved ejection fraction and a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or higher to receive once-weekly semaglutide (2.4 mg) or placebo for 52 weeks. The dual primary end points were the change from baseline in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS; scores range from 0 to 100, with higher scores indicating fewer symptoms and physical limitations) and the change in body weight. Confirmatory secondary end points included the change in the 6-minute walk distance; a hierarchical composite end point that included death, heart failure events, and differences in the change in the KCCQ-CSS and 6-minute walk distance; and the change in the C-reactive protein (CRP) level. RESULTS: The mean change in the KCCQ-CSS was 16.6 points with semaglutide and 8.7 points with placebo (estimated difference, 7.8 points; 95% confidence interval [CI], 4.8 to 10.9; P<0.001), and the mean percentage change in body weight was -13.3% with semaglutide and -2.6% with placebo (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001). The mean change in the 6-minute walk distance was 21.5 m with semaglutide and 1.2 m with placebo (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001). In the analysis of the hierarchical composite end point, semaglutide produced more wins than placebo (win ratio, 1.72; 95% CI, 1.37 to 2.15; P<0.001). The mean percentage change in the CRP level was -43.5% with semaglutide and -7.3% with placebo (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001). Serious adverse events were reported in 35 participants (13.3%) in the semaglutide group and 71 (26.7%) in the placebo group. CONCLUSIONS: In patients with heart failure with preserved ejection fraction and obesity, treatment with semaglutide (2.4 mg) led to larger reductions in symptoms and physical limitations, greater improvements in exercise function, and greater weight loss than placebo. (Funded by Novo Nordisk; STEP-HFpEF ClinicalTrials.gov number, NCT04788511.).
Overview
CoChat Summary
TL;DR
In STEP-HFpEF, once-weekly semaglutide 2.4 mg versus placebo in patients with heart failure with preserved ejection fraction and obesity improved heart failure symptoms/physical limitations, body weight, exercise function, a hierarchical composite outcome, and CRP over 52 weeks. Semaglutide also had fewer serious adverse events than placebo.
Key findings
- Dual primary end points: mean KCCQ-CSS change was 16.6 points with semaglutide vs 8.7 with placebo (estimated difference, 7.8 points; 95% CI, 4.8 to 10.9; P<0.001), and mean body weight changed by -13.3% vs -2.6% (estimated difference, -10.7 percentage points; 95% CI, -11.9 to -9.4; P<0.001).
- Confirmatory secondary end points: 6-minute walk distance changed by 21.5 m vs 1.2 m (estimated difference, 20.3 m; 95% CI, 8.6 to 32.1; P<0.001); hierarchical composite win ratio was 1.72 (95% CI, 1.37 to 2.15; P<0.001); CRP changed by -43.5% vs -7.3% (estimated treatment ratio, 0.61; 95% CI, 0.51 to 0.72; P<0.001).
- Safety: serious adverse events occurred in 35 participants (13.3%) with semaglutide vs 71 (26.7%) with placebo (P<0.001), driven mainly by fewer cardiac disorder events (7 [2.7%] vs 30 [11.3%]; P<0.001); discontinuation due to any adverse event occurred in 35 vs 14 participants, predominantly gastrointestinal events.
- Exploratory: adjudicated heart failure hospitalization or urgent visit occurred in 1 semaglutide participant vs 12 placebo participants (hazard ratio, 0.08; 95% CI, 0.00 to 0.42).
Methods
- Randomized, double-blind, placebo-controlled trial at 96 sites in 13 countries; 529 participants with HFpEF, BMI ≥30, LVEF ≥45%, NYHA class II–IV, KCCQ-CSS <90, and 6-minute walk distance ≥100 m were assigned 1:1 to once-weekly semaglutide 2.4 mg or placebo for 52 weeks plus 5-week follow-up.
- Dual primary end points were change in KCCQ-CSS and percentage change in body weight at week 52; confirmatory secondary end points included 6-minute walk distance, a hierarchical composite (death, heart failure events, KCCQ-CSS and 6-minute walk differences), and CRP.
- Efficacy was analyzed in the full analysis population using the treatment policy estimand; continuous end points used ANCOVA, the hierarchical composite used a win-ratio approach, and safety was analyzed in the as-treated safety population.
Limitations
- Stated in the paper: the number of non-White participants was low, which may limit generalizability; the trial was not adequately powered for clinical events such as heart failure hospitalizations/urgent visits; follow-up was limited to 1 year; specific glycated hemoglobin data were not collected beyond excluding diabetes; and SGLT2 inhibitor use was low.
- Evident from the text: the trial population was 95.8% White, median age 69 years, all with BMI ≥30, and patients with diabetes were excluded, so findings may not generalize to more diverse, younger, non-obese, or diabetes populations.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
17 Valid · 2 Not valid · 4 Not checked · 90 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that obesity and excess adiposity are not simply coexisting conditions but may play a role in the development and progression of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Background calls obesity a risk factor for incident heart failure, and the Discussion links severe obesity to more adverse outcomes and hospitalizations among patients who already have HFPEF. These findings support the hedged suggestion that obesity may matter beyond coexistence, but the paper does not establish a role for excess adiposity specifically in the development or progression of HFPEF; its HFPEF analysis concerns BMI and outcomes. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. source
The Discussion (page not provided) states that increased adiposity promotes conditions that contribute to HFpEF pathophysiology. The Conclusions (page not provided) add that adipose deposition may have adverse consequences for HFpEF. Together, these support the citing sentence’s hedged claim that adiposity may play a role rather than merely coexist with the disease. (LLM, conf=0.88)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The main text explicitly says that excess adipose tissue likely plays a pivotal role in the development and progression of HFpEF. It also describes evidence linking adiposity to incident HFpEF and adverse outcomes in established HFpEF. This supports the citing sentence’s hedged claim that obesity and excess adiposity may contribute rather than merely coexist. (LLM, conf=0.94)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5 describes obesity-related changes that can lead to HFpEF. Section 5.8.1 links visceral adiposity to the risk of developing HFpEF and reports that central adiposity is associated with worse outcomes in patients who have it. Together, these passages support the hedged claim that excess adiposity may contribute to development and progression. (LLM, conf=0.92)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“growing evidence suggests that adipose tissue may play a pivotal role in the development, progression, and adverse outcomes of heart failure with preserved ejection fraction. 4-8”
What the sources say
- Partly supportedcites [4] 4. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-31. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a U-shaped association between BMI and adverse outcomes in patients with HFpEF, and the paper describes obesity as a risk factor for developing heart failure generally. It does not establish a role for adipose tissue in HFpEF progression or specifically in its development; BMI is not a direct measure of adipose-tissue activity. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [5] 5. Newman AB, Lee JS, Visser M, et al. Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am J Clin Nutr 2005; 82: 872-8. source
- Partly supportedcites [6] 6. Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failure with preserved ejection fraction. JACC Heart Fail 2018; 6: 640-9. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says increased adiposity contributes to HFpEF pathophysiology and links abdominal fat to impaired exercise tolerance in older obese patients. This supports a possible role for adipose tissue, but the paper does not establish its role in HFpEF progression or in adverse clinical outcomes. (LLM, conf=0.85)
- Supportedcites [7] 7. Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018; 6: 1008-10. source
The paper’s main text explicitly says that excess adipose tissue likely plays a pivotal role in HFpEF development, progression, and adverse outcomes. It also identifies visceral adipose tissue as especially important in metabolic/obese HFpEF. (LLM, conf=0.95)
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Section 5.8.1 (page not provided) describes a pivotal role for visceral adipose tissue in obese HFpEF, linking it to both incident HFpEF risk and worse outcomes. Section 5.3 (page not provided) describes mechanisms by which epicardial adipose tissue may impair cardiac function and reports associations with greater disease severity and hospitalization or death. Together, these passages support the claim’s hedged wording. (LLM, conf=0.90)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Even when patients have well compensated heart failure with preserved ejection fraction and are in stable condition, they have markedly impaired objectively measured physical function. 34”
What the sources say
- Partly supportedcites [34] 34. Pandey A, Shah SJ, Butler J, et al. Exercise intolerance in older adults with heart failure with preserved ejection fraction: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78: 1166-87. sourceExperimental — accuracy not yet measured
In ‘EI: A Key Manifestation of HFpEF’ (page unavailable), the review reports that objectively measured peak oxygen uptake is, on average, 35% lower in patients with HFpEF than in matched healthy controls. This supports marked impairment, but the passage does not establish that the patients were well-compensated and clinically stable. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our findings of substantial reductions in symptoms and physical limitations and improvements in exercise function that parallel a greater degree of weight loss with semaglutide than with placebo may offer insights into the long-standing controversy surrounding weight (and weight loss) in persons with heart failure. 8”
What the sources say
- Supportedcites [8] 8. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res 2023; 118: 3434-50. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“previous global clinical trial programs of agents such as SGLT2 inhibitors, sacubitrilvalsartan, and spironolactone for heart failure with preserved ejection fraction showed only modest changes in KCCQ scores (ranging from 0.5 to 2.3 points). 31-33”
What the sources say
- Partly supportedcites [31] 31. Butler J, Filippatos G, Jamal Siddiqi T, et al. Empagliflozin, health status, and quality of life in patients with heart failure and preserved ejection fraction: the EMPEROR-Preserved trial. Circulation 2022; 145: 184-93. sourceExperimental — accuracy not yet measured
The Discussion (page not available) reports modest KCCQ improvements in the TOPCAT spironolactone and PARAGON-HF sacubitril/valsartan trials, while the Results report modest improvements with the SGLT2 inhibitor empagliflozin. These passages support the overall characterization, but they do not establish the stated range of 0.5 to 2.3 points. (LLM, conf=0.86)
- Partly supportedcites [32] 32. Kosiborod MN, Bhatt AS, Claggett BL, et al. Effect of dapagliflozin on health status inpatients with preserved or mildly reduced ejection fraction. J Am Coll Cardiol 2023; 81: 460-73. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes the KCCQ benefit with dapagliflozin in DELIVER as modestly higher than that with empagliflozin in EMPEROR-PRESERVED, and mentions the sacubitril-valsartan PARAGON-HF trial. It does not establish the claimed 0.5–2.3-point range across those trials or report a corresponding spironolactone result. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [33] 33. Lewis EF, Kim HY, Claggett B, et al. Impact of spironolactone on longitudinal changes in health-related quality of life in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2016; 9(3): e001937. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
45 more claims · 1 with their cited sources checked
Create a free account to see all 113 claims and every source verdict.
- Probably not a substantial claim. 33
- It may state two separate claims as one. 43
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and there is evidence that semaglutide 2.4 mg improves heart failure with preserved ejection fraction in individuals without diabetes by a potentially direct or indirect effect on epicardial adipose tissue (Kosiborod et al, 2023;Myasoedova et al, 2023).”
From Emerging pharmacotherapies for obesity: A systematic review (2025) · cites this paper as Kosiborod et al, 2023
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both semaglutide and tirzepatide reduce the severity of heart failure with preserved ejection fraction (65, 66).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [65]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with HFpEF and obesity (with and without diabetes), semaglutide 2.4 mg once weekly for 52 weeks improved symptoms, physical function, exercise function and bodyweight compared to placebo (STEP HFpEF and STEP HFpEF DM clinical trials) [59,91].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [59]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
From Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes (2025) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“weight-loss interventions (eg, gastric bypass surgery and glucagon-like peptide-1 receptor agonists) can reduce the risk of incident HF and improve symptoms in patients with established HFpEF.16–20”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [19]
Experimental — accuracy not yet measured
39 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationO'Connor (2009) · doi:10.1001/jama.2009.454 · Cited by 2,173
Green, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
Self-citationHeart Failure With Preserved, Borderline, and Reduced Ejection Fraction
Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.074 · Cited by 1,110
Epidemiology of Heart Failure: A Contemporary Perspective
Roger, V. L. (2021) · Circulation Research · doi:10.1161/circresaha.121.318172 · Cited by 946
Kitzman, D. W., Brubaker, P., Morgan, T., Haykowsky, M., Hundley, G., Kraus, W. E., Eggebeen, J., & Nicklas, B. J. (2016) · JAMA · doi:10.1001/jama.2015.17346 · Cited by 921
Self-citationBordicchia, M., Liu, D., Amri, E.-Z., Ailhaud, G., Dessì-Fulgheri, P., Zhang, C., Takahashi, N., Sarzani, R., & Collins, S. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59701 · Cited by 872
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Self-citationEvaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Self-citation
Cited by
Items 901–1,000 of 1,639
Clinical and preclinical obesity: cardiovascular implications of a new diagnostic paradigm
Nam, G. E. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e6 · Cited by 4
“Clinical trials such as STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) showed that weight reduction with semaglutide significantly improved symptoms and quality of life in patients with HFpEF and obesity [26].”
The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights from 2024
Bhatt, H. V., Fritz, A. V., Feinman, J. W., Subramani, S., Malhotra, A. K., Townsley, M. M., Weiner, M. M., Sharma, A., Teixeira, M. T., Nguyen, B., et al. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.10.030 · Cited by 3
Arty, F., Shreya, D., Chaudhry, A., & Sohini, S. (2025) · Cureus · doi:10.7759/cureus.87605 · Cited by 5
Toward a New SUMMIT in Heart Failure with Preserved Ejection Fraction
Felker, G. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2415551 · Cited by 2
Koman, A. M., Przygodzka, S., Gadżała, K., Janik, I., Pliszka, M., Palacz, K. A., Kułak, K. B., Sztybór, I., Kuśmierska, M., & Chamera-Cyrek, K. (2024) · Quality in Sport · doi:10.12775/qs.2024.16.52659 · Cited by 2
Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?
Kylies, D., Dreher, L., & Wenzel, U. O. (2026) · Current Hypertension Reports · doi:10.1007/s11906-026-01374-7 · Cited by 2
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3
Ambrosini, S., Costantino, S., Mohammed, S. A., Gorica, E., Herwig, M., van Heerebeek, L., Mengozzi, A., Karsai, G., Hornemann, T., Dzemali, O., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.25.605217 · Cited by 2
Incretin-mediated control of cardiac energy metabolism
Chan, J. S. F., Shafaati, T., & Ussher, J. R. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0011 · Cited by 2
Sato, R., & von Haehling, S. (2024) · Med · doi:10.1016/j.medj.2023.12.012 · Cited by 2
Palau, P., Núñez, J. E., Domínguez, E., de la Espriella, R., Núñez, G., Flor, C., de Amo, I., Casaña, J., Calatayud, J., Ortega, L., et al. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102839 · Cited by 2
Self-citationBody mass index, exercise capacity and functional status in chronic heart failure
Noumegni, S. R., Kazé, A. D., Fonarow, G. C., & Echouffo-Tcheugui, J. B. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04998-w · Cited by 4
“…among individuals with chronic HF to improve functional status, ideally using glucagon-like peptide-1 receptor agonists (GLP-1RA), which have been shown to be associated with improvements in heart failure symptoms and functional capacity among individuals with established heart failure [9, 12].”
Spagnolin, M., Fazzini, L., Giaccherini, C., D’Elia, E., Chiesa, E., Zucchi, A., Gavazzi, A., Senni, M., & Gori, M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag037 · Cited by 2
Self-citationHeart Failure Pharmacotherapy Over the Past 30 Years: Boats Against the Current
Beavers, C. J. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.05.014 · Cited by 2
Kim, H. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e4 · Cited by 2
Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Left Ventricular Assist Devices
Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Forst, B. J., Allam, M., Mee, X. C., Lim, G. K., Bcharah, G., Barry, T., Farina, J., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15379 · Cited by 3
Repetti, G. G., Abel, E. D., Tontonoz, P., & Sallam, T. (2026) · Circulation Research · doi:10.1161/circresaha.126.328680 · Cited by 3
Glucagon-like peptide-1 receptor agonists in patients with anthracycline related cardiac dysfunction
Scalia, I. G., Ibrahim, R., Abdelnabi, M. H., Pham, H. N., Farina, J., Pereyra, M., Lee, K. S. S., Tamarappoo, B. K., Arsanjani, R., & Ayoub, C. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00381-y · Cited by 6
Nowakowski, M., Mazuruk, M., Nogajski, Ł., Mączewski, M., Czerwińska, H., Kurpias, M., Mączewski, M., & Paterek, A. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03126-y · Cited by 4
“Glucagon-like peptide 1 (GLP-1) receptor agonists also reduce EAT [61]; however, clinical trials suggest a lack of benefit—and even a potential signal of harm—in HFrEF [62, 63], while demonstrating beneficial effects in HFpEF [64].”
A novel high dimensional approach to assess heterogeneous treatment effect in claims data
Wang, T., Pate, V., Wyss, R., Buse, J. B., Kosorok, M. R., & Stürmer, T. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf127 · Cited by 3
Voetmann, L. M., Rolin, B., Kirk, R. K., Knudsen, L. B., Merkestein, M., Ahnfelt‐Rønne, J., Kodal, A. L. B., Jessen, C., Ozen, A. I., Pyke, C., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70510 · Cited by 3
“45,46 The GLP-1RA class of effective anti-diabetic and weight loss drugs has recently been shown to reduce the risk of cardiovascular events by 20% and similarly reduce the hsCRP by 39% (SELECT trial) 47 and 43.5% (STEP trial) 48 with an acceptable safety profile.”
InfluentialYoon, M., Park, J. J., & Greenberg, B. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag025 · Cited by 2
Belančić, A. (2025) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70130 · Cited by 3
Péč, M. J., Jurica, J., Bolek, T., Škorňová, I., Péčová, M., Cingel, M., Horná, S., Stančiaková, L., Staško, J., Tóth, Š., et al. (2025) · Metabolites · doi:10.3390/metabo15020091 · Cited by 2
The Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Manoria, P. C. (2025) · Cureus · doi:10.7759/cureus.96713 · Cited by 7
Dalpiaz, H., Masi, S., Piludu, S., Agnoletti, D., Piani, F., Fiorini, G., & Borghi, C. (2025) · Heart · doi:10.1136/heartjnl-2024-324847 · Cited by 4
Semaglutide for Alzheimer's disease after evoke and evoke+
Schneider, L. S. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00514-3 · Cited by 3
Intravenous iron therapy in heart failure with preserved ejection fraction: how far have we walked?
Kittipibul, V., & Mentz, R. J. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae490 · Cited by 2
Alawoad, Z., Jensen, J., Schou, M., Ahmed, N., Attia, A. E., Rao, S., Rahimi, K., & Wamil, M. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10577-0 · Cited by 4
“…endpoints that reflect symptom relief, functional capacity, and quality of life, as seen, for example, in the DEFINE-HF (Dapagliflozin Effects on Biomarkers, Symptoms and Functional Status in HF) [21] and STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) [22] trials.”
Self-citationManagement of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
Ray, S., Kapoor, N., Deshpande, N., Chatterjee, S., Kumar, J. S., Tantia, O., Goyal, G., Mukherjee, J. J., & Singh, A. K. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2330468 · Cited by 3
“Furthermore, semaglutide has shown significant beneficial effects in people with obesity with heart failure with preserved ejection fraction (HFpEF) in the STEP HFpEF trial [102].”
BackgroundKo, D., Kim, D. H., Tan, F. X. N., Ho, G. J. K., Chandra, R., Xuan, Z. Z., Tham, E. K. J., Tang, N. S. Y., Yang, H. S., Koh, J. W. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102614 · Cited by 3
“51 Additionally, emerging real-world data have identified a potential link between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), which was not previously reported in RCTs, most likely because NAION is extremely rare; even pooling all the RCTs together, the signal did not…”
Cardiovascular effects of semaglutide and tirzepatide and their potential for cardioprevention
Cherkashin, D. V., Салухов, В. В., & Khalimov, Y. S. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-323 · Cited by 2
Bonga, K. N., & Padhan, M. (2026) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10565 · Cited by 2
Teng, Y., Bian, W., Li, Q., Eyk, J. E. V., Yan, X., & Zhang, S. Y. (2026) · Journal of Translational Internal Medicine · doi:10.1515/jtim-2026-0043 · Cited by 4
“[147] Treatment with tirzepatide, a long-acting dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, was also associated with lower cardiovascular risk in obesity-related HFpEF; however, these benefits were driven primarily by reductions in worsening HF events rather…”
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
A review regarding the article ‘Semaglutide and heart failure: Updated meta-analysis’
Dou, Y. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102736 · Cited by 2
Austin, R. C., Khair, E., Blakeman, T., Hossain, M. Z., Sowden, E., Chew-Graham, C. A., Forsyth, F., & Deaton, C. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-092993 · Cited by 3
Courtney, L. A., Clements, J. N., Isaacs, D. M., Pitlick, J. M., Reece, S. W., & Whitley, H. P. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103314 · Cited by 3
Gupta, N., Uwawah, T. D., Singh, K., Madan, H., Kumar, S., Midha, B., Soni, K., Singh, A., Bhogal, A., & Jain, A. (2024) · Cureus · doi:10.7759/cureus.64668 · Cited by 4
“Table 1 describes the baseline characteristics of the selected studies [19-22].”
BackgroundMethodResultInfluentialHundertmark, M., Siu, A. G., Matthews, V., Lewis, A., Grist, J. T., Patel, J., Chamberlin, P., Sarwar, R., Yavari, A., Dehbi, H., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.04.24.591019 · Cited by 2
Christensen, J. C., Anand, S., Chertow, G. M., Lyden, K. A., Sarwal, A., Bjordahl, T. S., Boucher, R. E., Mohammed, A. A., Oro, E. G., Akramimoghaddam, F., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107766 · Cited by 2
National Consensus on Semaglutide in Cardiology: From Clinical Evidence to Clinical Translation
Chopra, H., Mehta, A., Ponde, C., Nanda, N. C., Wander, G., Oomman, A., KERKAR, P., Routray, S., Ratnaparkhi, G., Advani, P., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1375 · Cited by 2
Arora, P., Dabbous, F. M., Udayachalerm, S., Saiontz-Martinez, C., Zhao, Z., Hartaigh, B. Ó., Fabricatore, A. N., Bassan, M., Álvarez, S., & Fitch, A. (2026) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2610206 · Cited by 4
“The HRQoL benefits of semaglutide 2.4 mg treat-ment have been previously demonstrated in patients with overweight or obesity [30,31]; however, this study did not assess the impact of semaglutide on indirect costs, including HRQoL.”
InfluentialTreatment options for heart failure in individuals with overweight or obesity: a review
Nasoufidou, A., Stachteas, P., Karakasis, P., Kofos, C., Karagiannidis, E., Klisic, A. N., Popovic, D. S., Koufakis, T., Fragakis, N., & Patoulias, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2479378 · Cited by 3
Harbi, M. H., Ashour, A. M., Alorfi, N. M., Aldurdunji, M. M., Wali, S. M., & Alzahrani, Y. A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1764664 · Cited by 4
New perspectives on semaglutide in cardiovascular disease
Seferovic, P. M., & Polovina, M. M. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01734-9 · Cited by 2
Wu, C., Sharma, A., Edwards, J. D., Liu, P. P., Wu, C. F., Podolsky, S., Kapral, M. K., Lanctôt, K. L., MacIntosh, B. J., Cogo‐Moreira, H., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.05.022 · Cited by 4
Comparative value of HFpEF scores for risk stratification in patients with unexplained dyspnoea
Dhont, S., Moura-Ferreira, S., Bekhuis, Y., Falter, M., Milani, M., L’Hoyes, W., Hoedemakers, S., Soens, L., Jacobs, A., Schutter, S. D., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag072 · Cited by 2
Damman, K., ter Maaten, J. M., Mayne, K. J., Bolignano, D., Brown, E. M., da Costa, B. R., Dagre, A. G., Gansevoort, R. T., Gavina, C., Goette, A., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag098 · Cited by 34
Self-citationAlshaikh, A., Alshehri, A., Alzubaidi, L. M. Y., Elbadawi, H., Alsaeed, A. H., Almehthel, M. S., Aldahash, R., Alsabaan, F., Alotaibi, M. S., Alghamdi, K. A., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01826-4 · Cited by 2
“In the STEP-HFpEF trial (Kosiborod et al., 2023), once-weekly sema-glutide 2.4 mg demonstrated significant clinical benefits compared with placebo over 52 weeks.”
InfluentialHeart failure with preserved ejection fraction: a systemic condition of comorbidities
Harrington, J., & Pandey, A. (2026) · Heart Failure Reviews · doi:10.1007/s10741-025-10586-z · Cited by 4
Adropin protects against cardiac remodeling and metabolic dysfunction in a male mouse HFpEF model
Mushala, B. A. S., Stoner, M. W., Sharifi‐Sanjani, M., Manning, J. R., Bugga, P., Bhattarai, N., McMahon, B., Vandevender, A. M., Mullett, S. J., Kaufman, B. A., et al. (2026) · Clinical Science · doi:10.1042/cs20261501 · Cited by 7
Kassab, J. T., Drazner, M. H., & Thibodeau, J. T. (2026) · ESC Heart Failure · doi:10.1093/eschf/xvag111 · Cited by 3
Association between obesity and cardiac conduction defects
Mostafa, M. A., Kingsley, J. A., Soliman, E. Z., & Bhave, P. D. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1476935 · Cited by 2
“Notably, reductions were observed in left atrial volume, EAT volume, and biomarkers of fi brosis such as galectin-3 and TGF-β (36, 37).”
Kráľ, P., Holst‐Hansen, T., Olivieri, A., Ivanescu, C., Lamotte, M., & Larsen, S. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02932-8 · Cited by 3
“…been demon‑ strated for semaglutide 2.4 mg and liraglutide 3.0 mg and include delays in the occurrence of diabetes [30], improvements in heart function for people with heart failure and preserved ejection fraction [34, 35] or the avoidance of recurrent acute cardiovascular events or mortality [36].”
BackgroundInfluentialKishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Μatsumoto, T., Yagi, T., & Okada, M. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005364 · Cited by 5
“16– 18 The findings of these clinical trials suggest that GLP-1 RA may have additional benefits for patients with HF. 18 19 Although previous studies have tested the effectiveness of SGLT2i and GLP-1 RA individually in patients with HF or T2D, the effectiveness of combination therapy with SGLT2i…”
Joubert, M., Ducheix, S., Prieur, X., Cariou, B., & Manrique, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70012 · Cited by 2
Wasserstein, D. H., Whitford, T., Whiteson, H. Z., & Frishman, W. H. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001178 · Cited by 4
Chen, D., Wang, Z. Q., Xie, Z., Chen, Y., Luo, S., & Xu, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1785129 · Cited by 2
“…and HFpEF) recently demonstrated that semaglutide significantly reduced symptoms and physical limitations in patients with heart failure with preserved ejection fraction (HFpEF) and obesity, suggesting a direct cardioprotective role beyond weight loss (Schou et al., 2024; Kosiborod et al., 2023).”
Diagnosis and management of diastolic dysfunction in arterial hypertension
Blanch, P., & Freixa‐Pamias, R. (2025) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2025.06.002 · Cited by 3
Glucagon-Like Peptide 1 Receptor Agonists and Cardiovascular Disease
Ibe, T., & Borlaug, B. A. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-011141 · Cited by 4
Self-citationIntermuscular Adipose Tissue in CKD: A Window into Muscle Quality and Health?
Demirci, M., Dilaver, R. G., Roshanravan, B., Ikizler, T. A., & Gamboa, J. L. (2025) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000745 · Cited by 6
Reddy, Y. N. V., DeFranco, S., Lerman, A., Demmer, R. T., Chamberlain, A. M., Somers, V. K., & Borlaug, B. A. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.07.009 · Cited by 4
Self-citationL’hostellier, A., Kouanfack, C., Chazallon, C., Cardoso, S. W., Eholié, S. P., Banze, N., Halue, G., Capeau, J., Delaugerre, C., Moh, R., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-110560 · Cited by 2
“Importantly, weight gain in the DOR arms was quite low: median weight gains at weeks 48, 96, 148 and 192 were +1.4 kg, +0.9 kg, +1.6 kg and +1.1 kg in Drive-Forward, respectively; and +2.0 kg, +1.9 kg, +1.9 kg and +2 kg at the same weeks in Drive-Ahead.”
InfluentialKishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Open Heart · doi:10.1136/openhrt-2025-003382 · Cited by 2
Heart Failure with Preserved Ejection Fraction
Mathew, D., Elghoul, Y., Bhattacharya, S., & Smith, D. T. (2025) · Medical Clinics of North America · doi:10.1016/j.mcna.2025.04.006 · Cited by 2
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.106951 · Cited by 3
Kaye, A. D., Lien, N., Vuong, C. A., Schmitt, M. H., Soorya, Y., Abubakar, B. A., Muiznieks, L., Embry, N. J., Siddaiah, H. B., Kaye, A. M., et al. (2024) · Cureus · doi:10.7759/cureus.76101 · Cited by 6
Semaglutide in HFpEF and Obesity
Carbone, S., & Patel, K. V. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102665 · Cited by 2
Ahmad, O., Ibrahim, R., Pham, H. N., Abdelnabi, M. H., Elbenawi, H., Salih, M., Farina, J., Bhakta, M. D., Sell‐Dottin, K. A., Yang, E. H., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134042 · Cited by 2
Dhont, S., Ferreira, S. M., Galloo, X., Martens, P., Meekers, E. M., Tartaglia, K., Deferm, S., Herbots, L., Müllens, W., Verbrugge, F. H., et al. (2026) · Circulation · doi:10.1161/circulationaha.126.080833 · Cited by 4
Beshr, M. S., Shembesh, R. H., Kara, A. O., Salama, A. H., Arhaym, E., Abuajamieh, M., & Elhadi, M. (2025) · PubMed · doi:10.1097/crd.0000000000000915 · Cited by 2
The past, present, and future of mechanical circulatory and respiratory support
Gregory, S. D., Stephens, A. F., Heinsar, S., Arens, J., & Fraser, J. F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22148-4.00037-x · Cited by 2
McDonough, D. J. (2025) · Physiologia · doi:10.3390/physiologia5010010 · Cited by 3
“…this, we will develop and implement a multi-center randomized clinical trial examining the synergistic e ff ects of low-load/high-repetition resistance exercise with pharmacotherapy-induced weight loss on all-cause hospitalization and mortality in patients with HFpEF and obesity [52,53,139,140].”
Exercise Hemodynamics in Heart Failure with Preserved Ejection Fraction
Sarma, S. (2024) · Heart Failure Clinics · doi:10.1016/j.hfc.2024.08.003 · Cited by 1
Appetite and its Regulation: Are there Palatable Interventions for Heart Failure?
Lee, M. M. Y., Lean, M. E. J., Sattar, N. A., & Petrie, M. C. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00637-7 · Cited by 5
“In STEP-HFpEF ( n = 529) the GLP-1 receptor agonist semaglutide reduced weight by 10.7 %, improved health status, reduced a hierarchical composite endpoint, improved exercise function, and reduced inflammation and NT-proBNP [5].”
BackgroundInfluentialSelf-citationAntza, C., Jordan, J., McGowan, B. M., Ciudin, A., Filippi-Arriaga, F., Hönemann, J., Jelacovic, A., Nilsson, P. M., Tsioufis, K. P., Doehner, W., et al. (2026) · Journal of Hypertension · doi:10.1097/hjh.0000000000004285 · Cited by 1
Forsyth, F., & Deaton, C. (2024) · European Journal of Cardiovascular Nursing · doi:10.1093/eurjcn/zvae060 · Cited by 2
Nishikawa, K., Minamisawa, M., Yoshie, K., Suzuki, S., Tanaka, K., Okuma, Y., Kimura, K., Ueki, Y., Oguchi, Y., Kato, T., et al. (2025) · Circulation Reports · doi:10.1253/circrep.cr-25-0041 · Cited by 1
“These findings underscore the existence of a certain group of obese patients and suggest the need to reexamine interventions for obese patients with HF.”
InfluentialZou, S., Zhang, L., Wang, T., Wan, Y., Chai, K., Wang, S., Chen, M., Cai, J., Wang, H., & Yang, J.-F. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1674243 · Cited by 1
“Recently, two glucose-lowering drugs, SGLT2 inhibitor and GLP-1RA, were reported to improve the exercise tolerance of symptomatic HFpEF patients (8, 9).”
Bilak, J. M., Squire, I. B., Wormleighton, J. V., Brown, R. L., Hadjiconstantinou, M., Robertson, N., Davies, M. J., Yates, T., Asad, M., Levelt, E., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-094722 · Cited by 1
“19 21 Nonetheless, the studies exhibited limitations in participant phenotyping, offering very limited insights into cardiac structure and function beyond basic echocardiographic or MRI-based volumetric measurements.”
InfluentialSelf-citationBhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendera, K., Taha, A., Nadarajah, R., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116096 · Cited by 1
Self-citationGORD and GLP-1 receptor agonists: an emerging concern for gastroenterologists
Massey, B. T. (2023) · Gut · doi:10.1136/gutjnl-2023-331027 · Cited by 1
“These agents may also improve cardiovascular function 6 and help patients overcome addictions.”
BackgroundSurvodutide for the Treatment of Obesity
Platz, E., Kaplan, L. M., le Roux, C. W., Wharton, S., Burger, S., Hussain, S. A., Brueckmann, M., Startseva, E., Fey, C., Kosiborod, M., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.102780 · Cited by 3
Self-citationAnker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Self-citationSaeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
“This hypothesis is supported by the observation that a linear relationship was observed between weight loss and improvement in KCCQ-CSS in the STEP HFPEF trial [41, 42 ].”
InfluentialEfficacy and safety of semaglutide in patients with heart failure: A meta-analysis
Li, X., Liu, G., & Liu, Y. (2025) · Precision medication. · doi:10.1016/j.prmedi.2025.100064 · Cited by 1
HAJDUCZOK, A. G., DONALD, E. M., Maning, J., Youmans, Q. R., & Reza, N. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.10.001 · Cited by 1
O’Sullivan, J. W., Yun, T., Cai, R., Amar, D., Assimes, T. L., Chaudhari, A. S., Kim, D. S., Lewis, E. F., Haddad, F., Hormozdiari, F., et al. (2026) · medRxiv · doi:10.64898/2026.02.07.26345811 · Cited by 1
Coronary microvascular dysfunction in obesity—Current evidence, challenges, and unanswered questions
Huck, D. M., & Tamarappoo, B. K. (2025) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2025.102228 · Cited by 1
GLP-1 medications for weight-loss: a triumph of marketing over patient care
Chastain, R., Meadows, A., & Adams, L. (2026) · Fat Studies · doi:10.1080/21604851.2026.2646492 · Cited by 6
miRNA and mRNA expression signatures in a HFpEF large animal model
Chen, Y., & Seale, P. (2024) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00680.2024 · Cited by 1
Porterfield, L. R., Nadeem, S., Swanson, D., Hayek, S. S., & Vaughan, E. M. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01448-6 · Cited by 2
“…Kansas City Cardiomyopathy Questionnaire scores and exercise capacity in patients with and without diabetes in the STEP-HFpEF and STEP-HFpEF DM trials [ 43 , 44 ], and tirzepatide reduced a composite of cardiovascular death or worsening HF, primarily driven by fewer HF events, in SUMMIT [45 ].”
Natriuretic Peptides – Biomarker Companions Through Thick and Thin
Maeder, M. T. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3153 · Cited by 1
Beyond the prescription: A holistic GP approach to obesity and weight loss medications
Tyler, B. (2026) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380261420769 · Cited by 1
Holistic View of Tirzepatide’s Role in Obesity-Related HFpEF
Pagidipati, N. J. (2025) · Circulation · doi:10.1161/circulationaha.125.073439 · Cited by 1
Metadata
- Authors
- Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., Shah, S. J., Treppendahl, M. B., Verma, S., Abhayaratna, W., Ahmed, F. Z., Chopra, V., Ezekowitz, J., Fu, M., Ito, H., Lelonek, M., Melenovsky, V., Merkely, B., Núñez, J., Perna, E., Schou, M., Senni, M., Sharma, K., Van der Meer, P., von Lewinski, D., Wolf, D., & Petrie, M. C.
- Affiliations
- University of Copenhagen (DK)
- From the Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri–Kansas City School of Medicine, Kansas City (M.N.K.); Novo Nordisk, Søborg (S.Z.A., S.R., G.K.H., M.L.L., D.V.M., M.B.T.), and the Department of Cardiology, Herlev-Gentofte Hospital, University of Copenhagen, Herlev (M. Schou) — both in Denmark; the Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (B.A.B.); Baylor Scott and White Research Institute, Dallas (J.B.); the Department of Medicine, University of Mississippi, Jackson (J.B.); Diabetes Research Centre, University of Leicester, and National Institute for Health and Care Research Leicester Biomedical Research Centre (M.D.), Leicester, the Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester (F.Z.A.), and the School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow (M.C.P.) — all in the United Kingdom; the Department of Cardiovascular Medicine ...
- ORCID
- Kosiborod, Mikhail N.
- Borlaug, Barry A.
- Butler, Javed
- Davies, Melanie
- Hovingh, G. Kees
- Kitzman, Dalane W.
- Shah, Sanjiv J.
- Verma, Subodh
- Abhayaratna, Walter
- Ahmed, Fozia Z.
- Chopra, Vijay
- Ezekowitz, Justin
- Fu, Michael
- Ito, Hiroshi
- Lelonek, Małgorzata
- Merkely, Bela
- Núñez, Julio
- Perna, Eduardo
- Schou, Morten
- Senni, Michele
- Sharma, Kavita
- Wolf, Dennis
- Petrie, Mark C
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-21
- Volume
- 389
- Issue
- 12
- Pages
- 1069-1084
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4386154055
- Cited by
- 1,669
- References
- 41
- Citations by year
- 2026: 548 · 2025: 597 · 2024: 461 · 2023: 61
- FWCI
- 327.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- BOA (University of Milano-Bicocca) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Research Explorer (The University of Manchester) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, heart failure with preserved ejection fraction, obesity, weight loss, Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, C-reactive protein, GLP-1 receptor agonists, heart failure events, body weight, symptom burden
- MeSH terms
- Semaglutide, Glucagon-Like Peptides, Heart Failure, Humans, Obesity, Stroke Volume
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.